Dr. Bernstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4665 E Galbraith Rd
Fl 2
Cincinnati, OH 45236Phone+1 513-931-0775Fax+1 513-931-0779
Summary
- Dr. Jonathan Bernstein is an allergist/immunologist in Cincinnati, OH and is Professor of Clinical Medicine at the University of Cincinnati College of Medicine Department of Internal Medicine, Division of Internal Medicine Division of Rheumatology, Allergy and Immunology and partner of Bernstein Allergy Grouo and Bernstein Clinical Research Center. He received his medical degree from University of Cincinnati College of Medicine completed his IM residency at the Cleveland Clinic and Allergy fellowship at Northwestern University. He has been in practice 32 years. He is experienced in asthma, rhinitis., hereditary angioedema, mast cell disorders, allergic skin disorders including urticaria, progesterone hypersensitivity and atopic dermatitis and immunodeficiency. He has published over 400 peer reviewed articles and book chapters and is the editor of five books. He is involved in leadership roles in many professional organizations including President elect of the AAAAI.
Education & Training
- McGaw Medical Center of Northwestern UniversityFellowship, Allergy and Immunology, 1988 - 1990
- Cleveland Clinic FoundationResidency, Internal Medicine, 1985 - 1988
- University of Cincinnati College of MedicineClass of 1985
- Kenyon CollegeB.A., Chemistry, 1977 - 1981
Certifications & Licensure
- IN State Medical License 1995 - 2025
- KY State Medical License 2002 - 2025
- OH State Medical License 1986 - 2025
- IL State Medical License 1988 - 1990
- American Board of Allergy and Immunology Allergy & Immunology
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Top Doctor Cincinnati Magazine, 2000-2022
- Distinguished Clinician Award AAAAI, 2019
- Distinguished Clinician Award WAO, 2019
- Join now to see all
Clinical Trials
- Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES) Start of enrollment: 2006 Nov 01
- Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Start of enrollment: 2010 May 01
- Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema Start of enrollment: 2010 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents.Timothy Craig, Raffi Tachdjian, Jonathan A Bernstein, John Anderson, Christina Nurse
Annals of Allergy, Asthma & Immunology. 2024-12-01 - 1 citationsUCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities.Petra Staubach, Benedikt Bilo, Joachim W Fluhr, Karoline Krause, Kanokvalai Kulthanan
The Journal of Dermatological Treatment. 2024-12-01 - Immunotherapy and new treatments.Yaroslav Andrew Jakymec, Justin Greiwe, Jonathan A Bernstein
Current Opinion in Allergy and Clinical Immunology. 2024-12-01
Journal Articles
- Effect of Lanadelumab Compared with Placebo on Prevention of Hereditary Angioedema AttacksJonathan A Bernstein, Lawrence B Schwartz, Andrew M Smith, H James Wedner, Daniel Soteres, Timothy Craig, Douglas T Johnston, Aleena Banerji, Paula J Busse, William R ..., JAMA
- Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients with Chronic Idiopathic (Spontaneous) UrticariaJonathan A Bernstein, Michael D Tharp, Ivo Abraham, JAMA
- Correspondence and Reply ReplyJonathan Bernstein, MD, ScienceDirect
- Join now to see all
Books/Book Chapters
Lectures
- 3rd Annual North American Rhinology & Allergy Conference(NARAC)North American Rhinology & Allergy Conference(NARAC), Fajardo, Puerto Rico - 1/31/2013
Other
- Talanta. Portable method of measuring gaseous acetone concentrationsWorrall AD, Bernstein JA, Angelopoulos AP
8/1/2013 - New drug targets and future directions: EcallantideBernstein JA
http://www.futuremedicine.com
1/1/2011 - Allergic Rhinitis and Asthma: Role of Environmental DeterminantsBernstein JA
http://www.consultant.com
7/1/2006 - Join now to see all
Press Mentions
- Defining Treatment Success in Chronic Spontaneous UrticariaNovember 7th, 2024
- Novel Drug for Chronic Inducible Urticaria Delivers in Mid-Stage TrialOctober 29th, 2024
- Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible UrticariaOctober 26th, 2024
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: